Future Therapy of Cholangiocarcinoma | Zendy

Ruben R. Plentz | Zendy; Michael Bitzer | Zendy; Tim F. Greten | Zendy; Silvio Nadalin | Zendy; Arndt Vogel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Future Therapy of Cholangiocarcinoma

Author(s) -

Ruben R. Plentz,

Michael Bitzer,

Tim F. Greten,

Silvio Nadalin,

Arndt Vogel

Publication year - 2016

Publication title -

visceral medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.598

H-Index - 17

eISSN - 2297-475X

pISSN - 2297-4725

DOI - 10.1159/000450720

Subject(s) - medicine , intensive care medicine , general surgery

Bitzer: In early cholangiocarcinoma, operability is the most important issue. Despite low 5-year survival rates even in completely resected tumors (R0 resection), surgery is currently the only possibility to cure the disease. All patients are discussed in an interdisciplinary tumor board, based on magnetic resonance imaging or computed tomography scanning and, if necessary, endoscopic retrograde cholangiopancreatography (ERCP) as an additional investigation, depending on tumor localization, performance status, and laboratory values. In selected patients, fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning can contribute additional important details to the tumor staging.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research